Vectura Group Plc
VEC:LN
Overview
Company Profile
Vectura develops inhaled therapies principally for the treatment of respiratory diseases.
Classification
Financials
Corporate
Board of Directors
Bruno Angelici
Non-Executive Chairman
Bruno is a French national with an MBA (Kellogg School of Management) and business and law degrees from Reims. Bruno’s career includes senior management roles in pharmaceutical and medical device companies. Bruno retired from AstraZeneca in 2010 as Executive Vice President International after a 20-year career. He was responsible for Europe, Japan, Asia Pacific, Latin America, Middle East and Africa having originally joined as President of ICI Pharmaceuticals France. Prior to this, he was at Baxter, a US-based global supplier of medical devices. He has extensive international experience, including in the US, and brings a deep understanding to the Company of the medical device and pharmaceutical industries. External appointments Bruno is a Non-Executive Director of Smiths Group plc, a FTSE 100 technology group, and Novo Nordisk A/S, a global healthcare company and world leader in diabetes care. He is also a member of the Global Advisory Board of Takeda Pharmaceutical Company Ltd Japan, the largest pharmaceutical company in Asia, and a member of the Supervisory Board of Wolters Kluwer NV, a global information services and publishing company.
James Ward-Lilley
Chief Executive Officer
James is a BA Hons graduate, has an MBA and holds the Institute of Marketing Diploma. Prior to joining Vectura, James was Vice President Respiratory, Inflammation & Autoimmunity, GPPS (“Global Product and Portfolio Strategy”) at AstraZeneca. In this role James had responsibility for the development of AstraZeneca’s RIA (“Respiratory, Inflammation and Autoimmunity”) strategy which included the acquisitions of Almirall’s respiratory business and Pearl Therapeutics. Prior to this, James led the AstraZeneca Investor Relations team from 2011 to 2012. James had an extensive career at AstraZeneca, spanning 28 years across a variety of commercially focused roles. James progressed from sales and marketing roles in the UK through to Country Head of Belgium and Luxembourg a position he held between 2002 and 2005. He then led AstraZeneca\'s business in China to become the number one pharmaceutical company in the market in 2008. James went on to become Regional Vice President for Central Eastern Europe and the Middle East where the business enjoyed a period of strong growth with sales doubling to $2billion during his tenure.
Andrew Oakley
Chief Financial Officer and Company Secretary
Andrew holds a Bachelor of Economics Degree from Macquarie University and an MBA from London Business School and has been a Member of the Australian Institute of Chartered Accountants since 1987. Prior to Vectura, Andrew was the Chief Financial Officer at the Swiss bio-pharmaceutical companies Actelion Ltd and Novimmune SA. Prior to joining Actelion, he served in a senior finance capacity for the global holding companies of Accenture, having previously held executive positions in major multinational building material companies and has also spent several years as an equity analyst with banks in Australia, UK and the US.
Trevor Phillips
Chief Operations Officer and President of US Operations
Trevor has a BSc in microbiology from the University of Reading and a PhD in microbial biochemistry from the University of Wales. He was awarded an MBA from Henley Management College in 1997. Prior to Vectura, Trevor gained extensive international experience in organisational leadership, management and pharmaceutical drug development in a number of senior roles, including positions as CEO and President of the US publicly held company Critical Therapeutics Inc, following six years as the company’s Chief Operating Officer. During his time at Critical Therapeutics, Trevor was involved in setting up commercial partnerships, product in-licensing and out-licensing, managing drug development and NDA filings, commercial product manufacturing and mergers and acquisitions. Between 1986 and 2002 Trevor held a number of management positions at Sepracor, Scotia Pharmaceuticals, Accenture, GlaxoWellcome Research and Development and Simbec Research Limited.
John Brown
Non-Executive Director and Senior Independent Director
John was previously Chairman of BTG plc and Axis-Shield plc. Until late 2003, John was Chief Executive of Acambis plc, a leading producer of vaccines to treat and prevent infectious disease. John is an Honorary Professor of Edinburgh University and is a Fellow of the Royal Society of Edinburgh. External appointments John is Chairman of CXR Biosciences Ltd, Mode Diagnostics Ltd, The Cell Therapy Catapult and the Roslin Foundation. He also chairs the Life Science Advisory Board for the Scottish government.
Susan Foden
Non-Executive Director
Susan has held various positions in venture capital and UK biotech companies. From 2000 to 2003 she was an Investor Director with the London-based venture capital firm Merlin Biosciences Limited, and was Chief Executive Officer of the technology transfer company Cancer Research Campaign Technology Ltd from 1987 to 2000. She studied biochemistry at the University of Oxford from where she obtained an MA and a DPhil.
Neil Warner
Non-Executive Director
Neil has significant financial and managerial experience in multinational businesses. He was Finance Director at Chloride Group plc, a position he held for 14 years until the company’s acquisition by Emerson Electric. Prior to this, he spent six years at Exel plc (formerly Ocean Group plc and acquired by Deutsche Post in December 2005), where he held a number of senior posts in financial planning, treasury and control. He has also held senior positions in Balfour Beatty plc (formerly BICC Group plc), Alcoa and PricewaterhouseCoopers and was a Non-Executive Director of Dechra Pharmaceuticals plc, where he was the Senior Independent Director and Chair of the Audit Committee. Neil has an economics degree from the University of Leeds and is a Fellow of the Institute of Chartered Accountants. External appointments Neil is the Non-Executive Chairman of Enteq Upstream plc, a specialist reach and recovery products and technologies provider to the upstream oil and gas services market.
Per-Olof Andersson
Non-Executive Director
Per-Olof was born in Sweden and studied medicine at Lund University. Per-Olof has an international R&D track record within the pharmaceuticals, bio-pharmaceuticals and speciality pharmaceutical industry and considerable experience in respiratory therapeutic development. In 2011, Per-Olof retired from Almirall where he was Executive Director for R&D and Member of the Board of Directors. Prior to joining Almirall in 2006, Per-Olof had a distinguished international career at Pharmacia and Pfizer over a period of nearly 20 years. Since 2011, Per-Olof has been an independent consultant advising biotech and pharmaceutical companies and in particular working with Almirall.